Allium Financial Advisors LLC Buys Shares of 1,360 Eli Lilly and Company (NYSE:LLY)

Key Points

• Allium Financial Advisors LLC acquired a new stake in Eli Lilly and Company, purchasing 1,360 shares worth approximately $1.12 million, which represents about 1.0% of its portfolio.
• Eli Lilly reported quarterly earnings of $3.34 EPS, missing estimates, with revenue of $12.73 billion compared to the expected $12.77 billion, but marked a 45.2% increase year-over-year.
• The company announced a quarterly dividend of $1.50 per share, with an ex-dividend date of August 15, reflecting a 0.74% dividend yield and a payout ratio of 48.82%.

Allium Financial Advisors LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,360 shares of the company's stock, valued at approximately $1,123,000. Eli Lilly and Company makes up 1.0% of Allium Financial Advisors LLC's investment portfolio, making the stock its 18th biggest position.

A number of other institutional investors have also recently bought and sold shares of LLY. Geode Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after buying an additional 291,875 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Eli Lilly and Company by 19.0% during the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Capital Research Global Investors lifted its holdings in shares of Eli Lilly and Company by 16.1% during the 4th quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock valued at $8,304,811,000 after buying an additional 1,493,673 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Eli Lilly and Company by 14.6% during the 4th quarter. Northern Trust Corp now owns 9,448,219 shares of the company's stock valued at $7,294,025,000 after buying an additional 1,204,337 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target for the company. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Finally, UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Price Performance

NYSE:LLY traded down $42.45 during trading hours on Tuesday, reaching $765.66. The company had a trading volume of 3,865,691 shares, compared to its average volume of 3,759,608. The stock has a 50-day moving average of $773.01 and a two-hundred day moving average of $800.67. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a market capitalization of $725.65 billion, a PE ratio of 62.30, a PEG ratio of 1.18 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.58 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.